In the Checkmate 9 × 8 study, subgroup analyses according to CMS subtypes demonstrated that in patients with CMS1 or CMS3 disease, there was a PFS benefit after 12 months of follow-up.44 Lastly, the preliminary results of the MEDITREME trial, in which the combination of FOLFOX with durvalumab and tremelimumab is being investigated as first-line therapy, showed an ORR of 61%, and 8.4 months PFS43 among patients with KRAS-mutated CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.